logo
  Join        Login             Stock Quote

Mylan (MYL) Launches Generic Version Of Pfizer's (PFE) Pulmonary Hypertension Drug

 November 13, 2012 09:09 AM
 


(By Balaseshan) Mylan Inc. (NASDAQ: MYL), a pharmaceutical company, said its subsidiary launched the generic version of Pfizer Inc.'s (NYSE: PFE) Revatio drug to treat pulmonary arterial hypertension in adults.

Mylan Laboratories Ltd. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sildenafil Citrate Tablets, 20 mg. Mylan has begun shipping this product.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

This product is the generic version of Pfizer's Revatio, which is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening.

Revatio Tablets, 20 mg, had U.S. sales of approximately $338.7 million for the 12 months ending September 30, 2012, according to IMS Health. Currently, Mylan has 172 ANDAs pending FDA approval representing $79.5 billion in annual sales.

On September 28, Mylan Pharmaceuticals Inc. has received final approval from FDA for its Abbreviated New Drug Application (ANDA) for Irbesartan Tablets USP, 75 mg, 150 mg and 300 mg, the generic version of Sanofi's Avapro.

The company also received final approval from the FDA for its ANDA for Irbesartan and Hydrochlorothiazide Tablets USP, 150/12.5mg and 300/12.5 mg, the generic version of Sanofi's Avalide.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Irbesartan Tablets are indicated for the treatment of hypertension and in patients with type 2 diabetic nephropathy, and Irbesartan and Hydrochlorothiazide Tablets are indicated for hypertension in patients not adequately controlled with a single drug, and as initial therapy in patients likely to need multiple drugs to achieve blood pressure control.

MYL closed Monday's regular session at $26.03. The stock has been trading between $17.22 and $26.55 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.